<DOC>
	<DOCNO>NCT01830322</DOCNO>
	<brief_summary>This Phase II study conduct assess safety efficacy CPI-613 patient metastatic pancreatic cancer . The primary outcome measure Overall Survival ( OS ) . The secondary outcome measure : change CA 19-9 , Quality Life ( QOL ) , Progression-Free Survival ( PFS ) , safety .</brief_summary>
	<brief_title>Safety Effectiveness Study CPI-613 and/or Gemcitabine Treat Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Data dose-escalated Phase I trials indicate CPI-613 safe effective metastatic pancreatic cancer ( Lee et al . 2012 ; Retter et al . 2012 ) . Accordingly , Phase II trial conduct assess safety efficacy CPI-613 patient metastatic pancreatic cancer . Primary Outcome Measure : - Overall Survival ( OS ) Secondary Outcome Measures : - Changes CA 19-9 - Quality Life ( QOL ) assessment - Progression-Free Survival ( PFS ) - Safety</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically cytologically confirm , measurable metastatic pancreatic adenocarcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Expected survival &gt; 2 month 18 year age old gender Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use accepted contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) study , must negative serum urine pregnancy test within 1 week prior treatment initiation . ( Note : Pregnant patient exclude effect CPI613 fetus unknown . ) Fertile men must practice effective contraceptive method study , unless documentation infertility exist . At least 2 week must elapse prior surgery hormonal therapy . Must fully recover acute toxicity prior treatment anticancer drug , radiotherapy anticancer modality ( return baseline status note recent treatment ) . Patients persist , stable chronic toxicity prior treatment ≤Grade 1 eligible , must document . Laboratory value ≤2 week must : Adequate hematologic ( white blood cell [ WBC ] ≥3500 cells/mm3 ≥3.5 bil/L ; platelet count ≥150,000 cells/mm3 ≥150 bil/L ; absolute neutrophil count [ ANC ] ≥1500 cells/mm3 ≥1.5 bil/L ; hemoglobin ( Hgb ) ≥9 g/dL ≥90 g/L ) . Adequate hepatic function ( aspartate aminotransferase [ AST/SGOT ] ≤3x upper normal limit [ UNL ] , alanine aminotransferase [ ALT/SGPT ] ≤3x UNL ( ≤5x UNL liver metastasis present ) , bilirubin ≤1.5x UNL ) . Adequate renal function ( serum creatinine ≤2.0 mg/dL 177 μmol/L , blood urea nitrogen [ BUN ] ≤25 mg/dL ) . Adequate coagulation ( `` International Normalized Ratio INR must &lt; 1.5 '' ) , unless treat anticoagulant . No evidence active infection serious infection within past month ; systemic fungal , bacterial , viral infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment . Consent participate study sign informed consent form Serious medical illness would potentially increase patient ' risk toxicity Any active uncontrolled bleeding patient bleed diathesis ( e.g. , active peptic ulcer disease ) Patients active central nervous system ( CNS ) epidural tumor Lactating female ( Note : Lactating female exclude effect CPI613 nursing child unknown ) Life expectancy le 2 month Unwilling unable follow protocol requirement Dyspnea minimal moderate exertion , patient pleural , pericardial , peritoneal effusion Active heart disease include limited symptomatic congestive heart failure , symptomatic coronary artery disease , symptomatic angina pectoris , symptomatic myocardial infarction , arrhythmias require medication , symptomatic congestive heart failure . Also patient history myocardial infarction &lt; 1 year prior registration , patient previous congestive heart failure ( &lt; 1 year prior registration ) require pharmacologic support Left Ventricular Ejection Fraction &lt; 50 % ) . A marked baseline prolongation QT/QTc interval ( e.g. , repeat exhibition QTc interval &gt; 470 ms. ) ; history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) . Requirement immediate palliative treatment kind include surgery Any condition abnormality may , opinion investigator , compromise safety patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>metastatic</keyword>
	<keyword>pancreatic</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>cancer</keyword>
</DOC>